BWXT: Q2 2026 delivered strong growth, raised outlook, and sharpened focus on core nuclear markets
Q2 2026 saw 18% revenue growth, robust backlog, and raised guidance for revenue, EBITDA, and EPS. Strategic moves included the $800M medical business sale and PCG acquisition, sharpening focus on core nuclear markets and expanding U.S. manufacturing.Based on BWX Technologies, Inc. [BWXT] Q2 2026 Au…